More recently, the STEP-HFpEF trial demonstrated that semaglutide, a GLP-1 receptor agonist, led to significant improvements in symptoms, physical function, and weight loss among patients with HFpEF and obesity, underscoring the potential of metabolic modulation in this population [40]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.